This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/526834-germany-vaccine-campaign-pace/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Disappointing trial of German-made CureVac coronavirus vaccine won’t hamper immunization at home – health ministry | Disappointing trial of German-made CureVac coronavirus vaccine won’t hamper immunization at home – health ministry |
| (2 months later) | |
| The unsatisfactory trial results of the German-made Covid-19 vaccine will have no effect on the pace of the national immunization campaign, the country’s government has said. | The unsatisfactory trial results of the German-made Covid-19 vaccine will have no effect on the pace of the national immunization campaign, the country’s government has said. |
| “The announcement does not have an impact on the speed of our vaccination rollout,” a German Health Ministry spokesperson said, as cited by Reuters. The spokesperson declined to comment on the results of the study. | “The announcement does not have an impact on the speed of our vaccination rollout,” a German Health Ministry spokesperson said, as cited by Reuters. The spokesperson declined to comment on the results of the study. |
| Tubingen-based pharmaceutical firm CureVac revealed the preliminary results of the late-stage trial of its CVnCoV coronavirus vaccine on Wednesday. The vaccine has shown a 47% efficacy rate, which “did not meet pre-specified statistical success criteria,” the company said in a statement. | Tubingen-based pharmaceutical firm CureVac revealed the preliminary results of the late-stage trial of its CVnCoV coronavirus vaccine on Wednesday. The vaccine has shown a 47% efficacy rate, which “did not meet pre-specified statistical success criteria,” the company said in a statement. |
| The trial involved around 40,000 volunteers in ten Latin American and European countries. | The trial involved around 40,000 volunteers in ten Latin American and European countries. |
| CureVac CEO Franz-Werner Haas said that efficacy may change after the company finishes analyzing the data. The emergence of several coronavirus variants “underlines the importance of developing next-generation vaccines,” Haas said. | CureVac CEO Franz-Werner Haas said that efficacy may change after the company finishes analyzing the data. The emergence of several coronavirus variants “underlines the importance of developing next-generation vaccines,” Haas said. |
| Karl Lauterbach, an MP from the Social Democratic Party of Germany, voiced disappointment with the results of the trial. “It’s a shame – the team from Tubingen deserved success,” he tweeted. | Karl Lauterbach, an MP from the Social Democratic Party of Germany, voiced disappointment with the results of the trial. “It’s a shame – the team from Tubingen deserved success,” he tweeted. |
| German company BioNTech, which is based in Mainz, developed the BNT162b2 vaccine, and partnered with the US-based pharmaceutical giant Pfizer for trials, logistics and manufacturing. | German company BioNTech, which is based in Mainz, developed the BNT162b2 vaccine, and partnered with the US-based pharmaceutical giant Pfizer for trials, logistics and manufacturing. |
| Apart from the Pfizer/BioNTech vaccine, Germany uses the Moderna, AstraZeneca/Oxford and Johnson & Johnson vaccines in its immunization campaign. As of Wednesday, 49.6% of the population have received at least one dose of a vaccine, and 28.8% were fully vaccinated, according to the government. | Apart from the Pfizer/BioNTech vaccine, Germany uses the Moderna, AstraZeneca/Oxford and Johnson & Johnson vaccines in its immunization campaign. As of Wednesday, 49.6% of the population have received at least one dose of a vaccine, and 28.8% were fully vaccinated, according to the government. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |